Last deal

$7.63M

Amount

Venture - Series Unknown

Stage

27.07.2005

Date

1

all rounds

$7.63M

Total amount

date founded

Financing round

General

About Company
Pharmacopeia is a biopharmaceutical company that focuses on discovering and developing therapeutics to address significant medical needs.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.1993

Number of employees

Company Type

For Profit

Last funding type

Venture - Series Unknown

IPO status

Private

Description

The company's internal program portfolio includes a dual-acting angiotensin and endothelin receptor antagonist in phase II clinical development for cardiovascular and renal diseases, as well as a muscle selective SARM agonist in phase I clinical development. They also have products in preclinical development for the treatment of multiple myeloma and various inflammatory diseases, and JAK3 inhibitors for dermatologic and ocular diseases. Pharmacopeia has strategic alliances with several pharmaceutical companies and operates as a subsidiary of Ligand Pharmaceuticals Inc.
Contacts
Similar Companies
999
Ariel Pharmaceuticals

Ariel Pharmaceuticals

Ariel Pharmaceuticals, Inc. is a biopharmaceutical company.

Sector

Pharmaceuticals and Biotechnology

Subsector

Pharmaceuticals

Keywords

Pharmaceuticals, Biotechnology, Health Care

Location

Broomfield, CO, USA
Drais Pharmaceuticals

Drais Pharmaceuticals

Drais Pharmaceuticals is a venture capital supported drug development company.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Pharmaceuticals, Biotechnology, Health Care

Location

Bridgewater Township, NJ, USA

total rounds

2

total raised

$33M
Pharmazz

Pharmazz

Pharmazz is a biopharmaceutical company that discovers, develops, and commercializes therapeutics for critical care medicine.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Pharmaceuticals, Biotechnology

Location

Willowbrook, IL, USA

total rounds

4

total raised

$13.32M

Egetis Therapeutics AB

Egetis is developing late-stage projects for the treatment of serious rare diseases in the orphan drug segment.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

total rounds

2

total raised

$42.49M
M&A Details
1

Acquired by

Ligand Pharmaceuticals

announced date

24.09.2008

Financials

Funding Rounds
1
1

Number of Funding Rounds

$7.63M

Money Raised

Their latest funding was raised on 27.07.2005. Their latest investor Balyasny Asset Management. Their latest round Venture - Series Unknown

Date 
Funding Round 
Investors 
Money Raised 
Lead 
27.07.2005
10
$7.63M
Co-Investors
Investors
10
0

Number of lead investors

10

Number of investors

Investor 
Lead 
Round 
Partners 
No
Venture - Series Unknown
No
Venture - Series Unknown
No
Venture - Series Unknown
Balyasny Asset Management

Balyasny Asset Management

Balyasny Asset Management delivers consistent, uncorrelated absolute returns.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services

Location

Chicago, IL, USA

count Of Investments

16

count Of Exists

2
Crestview Capital

Crestview Capital

The represented VC is a North American venture capital firm.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Venture Capital, Finance

Location

Winnetka, IL, USA

count Of Investments

2

count Of Exists

2
Highbridge Capital Management

Highbridge Capital Management

Highbridge Capital Management is a global alternative investment firm that offers credit and volatility focused solutions.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

New York, NY, USA

count Of Investments

24

count Of Exists

5
Acquisitions
1
Acquiree Name 
Date 
Price 
Acquisition Name 
Molecular Simulations, Inc. acquired by Pharmacopeia

Molecular Simulations, Inc. acquired by Pharmacopeia

acquirer

Pharmacopeia
Pharmacopeia

date

12.06.1998

type

Acquisition
Molecular Simulations, Inc.

Molecular Simulations, Inc.

Molecular Simulations provides molecular modeling and simulation software for research.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Software, Life Science, Biotechnology

Location

San Diego, CA, USA

People

Founders
2
Larry Bock
Larry Bock

Larry Bock

Larry Bock is the founder and organizer of the USA Science & Engineering Festival, and a former founder of the San Diego Science Festival. Mr. Bock is a Special Limited Partner to Lux Capital, a $100M nanotechnology-focused venture capital fund. He is a member of the Board of Directors of FEI Corporation (NASDAQ: FEIC), the leading supplier of tools for nanotechnology research. He is a General Partner of CW Ventures, a $100M life sciences venture capital fund. Mr. Bock was the founder and former executive chairman and initial CEO of Nanosys and the founder and initial CEO of Neurocrine Biosciences (NASDAQ: NBIX), Pharmacopeia (NASDAQ: PCOP), GenPharm International, which was acquired by Medarex for $100 million; Caliper Technologies (NASDAQ: CALP); Illumina Technologies (NASDAQ: ILMN), among numerous other firms. He was also a seed or early-stage investor in variety of firms, including Acceleron Pharma, Aurora Biosciences, Biosym Technologies, ekoVenture. Gen-Probe, Gensia Pharmaceuticals, Genocea Biosciences, IDEC Pharmaceuticals Magen Biosciences, Oclassen Pharmaceuticals Plexikon Pharmaceuticals, Poland Partners, Sequana Therapeutics, Sapphire Energy, Siluria, Sirtris Pharmaceuticals, Software Transformation, and Viagene. Mr. Bock started his career as a researcher in the early days at Genentech, the field of infectious diseases, where he was on the team that received the AAAS Newcomb Cleveland Prize for demonstrating the world’s first recombinant DNA vaccine. He was a Venture Capital Associate with Fairfield Ventures (now Oxford Bioventures). Larry and his wife, Diane, established the Larry and Diane Bock Chair in Nanotechnology at the University of California, Berkeley. They also founded Community Cousins, a non-profit foundation focused on breaking down racial barriers, that was selected by former Vice President Al Gore as one of 10 outstanding grass root efforts nationally. Larry is organizing the San Diego Science Festival with BioBridge of UCSD. He works extensively with the Sudanese and Burmese refugee’s networks in San Diego and is a tutor in math and sciences for Sudanese refugee children in St. Lukes Sudanese Refugee Network and a Mentor for Burmese refugee families through Jewish Family Services. Larry received his B.A. in Biochemistry (summa cum laude) from Bowdoin College and his M.B.A. from the Anderson School at UCLA.

current job

USA Science & Engineering Festival
USA Science & Engineering Festival

count Of Investments

4

count Of Exists

1

Larry Bock

John J. Baldwin
John J. Baldwin

John J. Baldwin

John Baldwin is the Co-Founder of iVIEW Therapeutics. John previously worked at Vitae Pharmaceuticals as a President. He attended the Univ. of Delaware and Univ. of Minnesota.

current job

Pharmacopeia
Pharmacopeia

organization founded

4

John J. Baldwin

Employee Profiles
9
John J. Baldwin

John J. Baldwin

Co-Founder and Chief Scientific and Technology Officer

Rene Belder

Senior Vice President of Clinical Development

Saiid Zarrabian

COO

Maria L. Webb

Vice President of Preclinical Research

Arthur Roke

Arthur Roke

Chief Accounting Officer & VP of Finance

Brian M. Posner

Brian M. Posner

Vice President, Finance

Larry Bock

Larry Bock

Founder & CEO

Activity

Recent News
0